Abstracts

221 – The Interplay Between Epigenetics and IFN-Signaling Modulate HIV Seeding and Persistence

Background The persistence of the HIV reservoir remains a major barrier for cure. Even under long-term antiretroviral therapy (ART), the reservoir endures and drives viral rebound during analytical treatment interruption (ATI). Evidence shows that smaller reservoir sizes on ART are associated with delayed rebound after ATI. Therefore, uncovering the mechanisms that naturally limit reservoir size…

260 – Characterizing SIV-Infected Plasmacytoid Dendritic Cell Aggregates in Rhesus Macaque Lymph Nodes

Background Lymphoid tissues are major sites of HIV/SIV viral replication and reservoir persistence. The full spectrum of cells that harbor persistent virus and can contribute to viral rebound are not well understood, hindering therapeutic targeting of these cell populations. We used multiplex fluorescent imaging to extensively characterize infected cells in lymphoid tissues of Rhesus macaques…

806 – Th17 and Treg Cytokines in Pregnant and Postpartum Women With HIV on Isoniazid in IMPAACT P1078

Background IMPAACT P1078 showed high rates of hepatotoxicity (~6-7%) in women with HIV (WWH) receiving daily isoniazid (INH), regardless of when INH was initiated and most commonly during postpartum (PP). T helper 17 cells (Th17) promote a pro-inflammatory environment that can drive progressive liver injury in non-pregnant adults, and regulatory T cells (Treg) mediate immune…

1020 – Projected Impact of Doxycycline PEP on Syphilis Incidence: Modeling Study in 4 US Cities

Background Syphilis incidence in the United States has risen sharply over the past two decades, especially among men who have sex with men (MSM), when cases declined following the rollout of Doxycycline post-exposure prophylaxis (doxy-PEP). Doxy-PEP has been shown to reduce syphilis acquisition risk in clinical trials, but its potential population-level impact remains unclear. We…

565 – Resistance in Primary HIV-1 Infection in France 2014-2025: Impact on First-Line Therapy and PrEP

Background Background: Transmitted HIV drug resistance (HIV-DR) may jeopardize the benefit of antiretroviral therapy (ART) and prevention (PrEP). Drug resistance testing is recommended at diagnosis of HIV in France and provides valuable insight for clinical decision-making and population-level monitoring. Methods Methods: We assessed the prevalence of HIV-DR and predicted susceptibility to HIV drugs among 3751…

1049 – Cost Effectiveness of Implementing Long-Acting PrEP in Eswatini: A Mathematic Modelling Study

Background Ending the HIV epidemic by 2030 remains a prime global objective. Pre-exposure prophylaxis (PrEP): dapivirine vaginal ring (ring PrEP), Tenofovir disoproxil fumarate-based oral PrEP (oral PrEP) and long-acting injectable PrEP (LA PrEP) offer substantial reductions in HIV transmission when adherence and retention are satisfactory. Using local epidemiological, programmatic, and cost data, we determined the…

600 – Performance of Prediction Scores for Steatotic Liver Disease in Thai PWH on InSTI-Based ART

Background Steatotic liver disease (SLD) is an increasingly recognized complication in people with HIV (PWH) on integrase strand transfer inhibitor (INSTI)-based ART. In resource-limited settings without transient elastography (TE) or ultrasound (US), simple prediction scores using available clinical information could help identify SLD, but their performance in PWH with INSTI-base ART era remains understudied. Methods…

878 – HIV Molecular Epidemiology in a Declining Generalized Epidemic: A Population-Based Study in Uganda

Background In African settings with high treatment coverage and declining incidence, it is unclear whether residual infections are driven primarily by external introductions or persistent local transmission. We examined sources of new infections in a multi-subtype epidemic during a period of expanded intervention access and falling incidence. Methods We analyzed gag (p24) and env (gp41)…

366 – Impact of the TKI Dasatinib on T-Cell Effector Functions in ART-Suppressed PWH (BCN04-DASA)

Background Dasatinib (DASA), a tyrosine kinase inhibitor (TKI) used to treat chronic myeloid leukemia, may help promote HIV-1 latency and reduce immune activation and senescence. However, DASA could impact T-cell effector functions by inhibition of TCR proximal kinases. Its impact on antigen-specific responses in people with HIV (PWH) is unclear. We evaluated the impact of low-dose…

914 – Area-Level Indicators as Proxies for Individual Socioeconomic Status in People With and Without HIV

Background Socioeconomic status (SES) is a key determinant of health outcomes for people with HIV (PWH). Many cohort studies collect individual-level measures of SES, while others (e.g., electronic health record-based cohorts) rely on area-level SES indicators as proxies. It is unclear which area-level indicators or geographic units best represent individual-level SES among PWH. Methods Using…